Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Flurbiprofen, a phenylalkanoic acid derivative, belongs to the class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs) with antipyretic and analgesic activity. It is primarily indicated as a pre-operative anti-miotic (in an ophthalmic solution) as well as orally for arthritis or dental pain. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
ln Vitro |
In a concentration- and time-dependent manner, flurbiprofen (2–20 nM; 12-48 hours) strongly inhibits the growth of SW620 cells [1]. For 24 hours, flurbiprofen (10 nM) decreases COX-2 expression [1]. By blocking COX-2, flurbiprofen (10 nM; 24 hours) reduces the expression of inflammatory factors [1]. By blocking COX-2, flurbiprofen (10 nM; 24 hours) encourages apoptosis in colorectal cancer cells [1]. An experiment on cell proliferation [1]
|
---|---|
ln Vivo |
In rats with adrenalectomy, flurbiprofen (0.3–4.8 mg/kg; oral; 4-5 doses) exhibits immediate anti-inflammatory effects [2]. In mice with high-fat diets, flurbiprofen (10 mg/kg; intraperitoneal injection; daily; for 6 days) reduces obesity [3].
|
Cell Assay |
Cell proliferation experiment [1]
Cell Types: SW620 cell Tested Concentrations: 2 nM, 4 nM, 10 nM, 20 nM Incubation Duration: 12 hrs (hours), 24 hrs (hours), 48 hrs (hours) Experimental Results: Inhibition of colorectal cancer cell proliferation. Western Blot Analysis[1] Cell Types: SW620 Cell Tested Concentrations: 10 nM Incubation Duration: 24 hrs (hours) Experimental Results: The protein and mRNA levels of COX-2 were Dramatically diminished. RT-PCR[1] Cell Types: SW620 Cell Tested Concentrations: 10 nM Incubation Duration: 24 hrs (hours) Experimental Results: diminished COX-2 mRNA expression levels Cell apoptosis analysis[1] Cell Types: SW620 Cell Tested Concentrations: 10 nM Incubation Duration: 24 hrs (hours) Experimental Results: The expression of Bcl2 was Dramatically diminished, and the expression of Bax and cleaved-caspase3 was Dramatically increased, but there was no effect on total caspase-3. |
Animal Protocol |
Animal/Disease Models: Rat[2]
Doses: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 4.8 mg/kg Route of Administration: po (po (oral gavage)) 4-5 times Experimental Results: Inhibition of acute inflammation. |
References |
[1]. Xiaobo Wang, et al. Flurbiprofen suppresses the inflammation, proliferation, invasion and migration of colorectal cancer cells via COX2. Oncol Lett. 2020 Nov; 20(5): 132.
[2]. E M Glenn, et al. The pharmacology of 2-(2-fluoro-4-biphenylyl)propionic acid (flurbiprofen). A potent non-steroidal anti-inflammatory drug. Agents Actions. 1973 Nov;3(4):210-6. [3]. Hosoi, T., et al., Flurbiprofen ameliorated obesity by attenuating leptin resistance induced by endoplasmic reticulum stress. EMBO Mol Med, 2014. |
Molecular Formula |
C15H13FO2
|
---|---|
Molecular Weight |
244.2609
|
CAS # |
5104-49-4
|
Related CAS # |
Tarenflurbil;51543-40-9;Flurbiprofen-d3;1185133-81-6;Flurbiprofen-d5;215175-76-1;Flurbiprofen-13C,d3;2747917-55-9
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CC(C1=CC=C(C2=CC=CC=C2)C(F)=C1)C(O)=O
|
InChi Key |
SYTBZMRGLBWNTM-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
|
Chemical Name |
2-(3-fluoro-4-phenylphenyl)propanoic acid
|
Synonyms |
Cebutid, dl-Flurbiprofen; Ansaid, Froben, Flurbiprofen, Antadys
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~409.40 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.0940 mL | 20.4700 mL | 40.9400 mL | |
5 mM | 0.8188 mL | 4.0940 mL | 8.1880 mL | |
10 mM | 0.4094 mL | 2.0470 mL | 4.0940 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.